Abstract
Abstract Background: Drug-resistant tuberculosis (DR-TB) can be a menace for TB elimination, making it crucial to identify the drivers of this multifaceted challenge. Now, as drug sensitivity results are available at the commencement of the treatment, DRTB patients can be delineated earlier rather than once landing into treatment failure. Objectives: The study was done to assess the sociodemographic and behavioral profile of DR-TB patients and its association with the drug-resistant pattern following the introduction of universal drug sensitivity testing in the program. Materials and Methods: A cross-sectional study was conducted at the DRTB center, Jabalpur. Record review was done for registered patients through the NIKSHAY portal, notification, laboratory registers, and PMDT treatment cards, for the period January 2018 to December 2019 excluding the transferred-out cases. Patients were contacted for any missing information. Data were analyzed using IBM SPSS version 20. The Chi-square test was applied for statistical significance considering P ≤ 0.05 to be significant at 95% confidence level. Results: Among 201 patients, the majority were males (62.2%) of the younger (18–30 years) age group (42.3%), residing below the poverty line (62.2%) in urban slums (40.8%). There was a preponderance of tobacco users (88.5%), whereas 22.9% were alcoholics. Nutritional status revealed 59.7% to be underweight, whereas 9% were overweight. Review of drug-resistant profile had shown multidrug resistance (MDR) to be most common (70.6%), followed by H resistance (13.4%) and others (MDR + fluoroquinolone [FQ] [10.4%], extensively drug-resistant [3.5%], H + FQ/second-line injectable [SLI]/LZ [1.5%], MDR + SLI [0.5%]). Belonging to lower socioeconomic strata, residing in urban slums, and being engaged in a labor class occupational profile carries a statistically significant association with MDR TB. Conclusion: MDR is the most common pattern of DR TB in the study population, proportionally higher in urban slum dwellers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
